Four-Year HIMALAYA Trial Data Reveals STRIDE’s Sustained Efficacy and Safety Profile in uHCC Patients
New findings from the HIMALAYA trial presented at the Symposium on Clinical Interventional Oncology 2023 indicate that STRIDE (single tremelimumab regular interval durvalumab) offers a significant survival advantage over sorafenib in patients with unresectable hepatocellular carcinoma (uHCC).
HCN Medical Memo
The HIMALAYA trial’s four-year follow-up data underscores the potential of STRIDE as a more effective and safer treatment option for patients with unresectable hepatocellular carcinoma. The sustained long-term benefits in overall survival rates make STRIDE a compelling choice for patient care, especially considering its tolerable safety profile.
- The study involved 1171 patients randomized into three groups: STRIDE (n=393), durvalumab (n=389), and sorafenib (n=389).
- The 36-month overall survival (OS) rates for STRIDE were 30.7%, compared to 19.8% for sorafenib.
- At 48 months, STRIDE continued to show higher OS rates (25.2%) versus sorafenib (15.1%).
- Treatment-related adverse events (TRAEs) occurred in 17.5% of STRIDE participants and 9.6% of sorafenib participants, with no new events for STRIDE after the primary analysis.
- Researchers emphasize STRIDE’s unprecedented long-term OS benefits and tolerable safety profile in a diverse uHCC population.
The estimated 5-year survival rate for hepatocellular carcinoma is only 18%.
- The main study outcomes were OS and serious TRAEs.
- No new serious safety events were observed for STRIDE, reinforcing its safety profile.
More on Liver Cancer